Social Media Ideas for Biopharma Nl

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

<![CDATA[BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment ]]>

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

<![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]>

Rinn Pharma & Biopharma to join NordicPharmaTrain network

The partnership could significantly strengthen Ireland's position within the European pharmaceutical research and innovation space. Read more: Rinn Pharma & Biopharma to join...

<![CDATA[Nuvation Bio’s Global Strategy]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Genmab

Genmab Anonymous (not verified) Mon, 07/13/2026 - 12:14 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

New €25 Million BioReliance Testing Facility Opens at Merck KGaA Global Headquarters in Germany

The 2,000-square-meter BioReliance facility in Darmstadt, Germany, will also offer GMP-compliant stability studies for monoclonal antibodies and cell therapies, addressing the grow...

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

Life science industry in Geneva on a roll 

Geneva’s life science industry is bound to western Switzerland's Health Valley ecosystem but is also growing in and of itself. The post Life science industry in Geneva on a roll ...

Biopharma Hungry for GLP-1 Receptor Agonist Manufacturing Skills

NIBRT predicts that the market for GLP-1 receptor agonist-based diabetes and obesity meds will increase demand for biopharmaceutical engineers with a mix of synthetic chemistry and...

UCB’s pipeline strategy in 2026: Doubling down on immunology and neurology

Discover how UCB’s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology. The post UCB’s pipeline strategy in 2026: Doubling down on immunology...

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Made Scientific announces MOU with NurExone for U.S. manufacturing and commercial supply partnership

NurExone Biologic Inc., a Frankfurt, Germany-based biotechnology company developing exosome-based regenerative therapies, said Aug. 13 that it and its wholly owned U.S. subsidiary,...

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

Romania’s Biofarm becomes part of Polish Polpharma

Romanian pharmaceuticals producer Biofarm (BVB: BIO) announced that it is joining the Polpharma Group, a new stage of joint development, in which "the solid market position, brand...

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

Inside one of Europe’s most advanced biotech innovation hubs

Discover M600 in Marburg: a 40,000 m² biotech campus bringing research, pilot-plant, and GMP together in one European innovation ecosystem. The post Inside one of Europe’s most ad...

Genomes to bioreactors: Saudi Arabia’s gene editing oncology push

Saudi Arabia is pairing gene editing breakthroughs with new biomanufacturing capacity, from CRISPR oncology therapies to CDMOs like Lifera, as it builds a full biotech pipeline. Th...

Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience

<![CDATA[Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Se...